Combination Cancer Therapy Clinical Trials Report 2028
Kuick Research Report Gives Comprehensive Clinical & Commercial Opportunity Insights More Than 600 Combination Cancer Drugs In Clinical Trials
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
- Combination Cancer Immunotherapy Market By 15 Different Cancers
- Insight On Clinically & Commercially Approved Cancer Immunotherapy Combinations
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
In last few years, the management of cancer has shifted towards combination therapy owing to its enhanced efficacy and specificity. The combination therapy aims to combine two or more drugs with synergistic mechanism of action towards the target cell. The aim of the combination therapy is to lower the doses of drugs as well as overcome the limitations of drug resistance associated with nontherapeutic approach. Till date a cocktail of combination therapy has gained approval for the management of cancer which has shown encouraging response in the global market.
For instance in June 2022, US FDA has granted approval to Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation. The rapid approval of the drug is due to encouraging response from phase-III clinical trial which has shown to enhance the outcomes in patients in comparison to monotherapy. Apart from this, fixed-dose combination of relatlimab (LAG-3 inhibitor) plus nivolumab sold under brand name Opdualag has also been approved for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma. The rapid approval of the novel combination has propelled the further preclinical and clinical studies in this segment.
Several novel combination cancer therapies are also awaiting approval and are therefore expected to enter the market in the forthcoming years. For instance in 2022, Immunity Bio has submitted biologic license application to US FDA to N-803 plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without Ta or T1 disease. The drug is expected to be available in the market by end of 2022 which will also boost its growth in the market. In 2021, US FDA also granted fast track designation to Ultimovac’s universal cancer vaccine UV1 in combination with checkpoint inhibitors (pembrolizumab or ipilimumab) in patients with unresectable or metastatic melanoma based on the encouraging results of phase-I study. The fast track designation is designed to facilitate the development and approval process of novel drug.
Large number of preclinical studies is evaluating novel combination therapies which are demonstrating encouraging response. Recently researchers have identified a new combination therapy consisting of a plant virus (cowpea mosaic virus) and an antibody that activates the immune system’s “natural killer” cells (anti-4-1BB). In preclinical studies with colon cancer mice, the novel combination eliminated at tumors and resulted in 100% survival. Apart from colon cancer, the combination was also validated on melanoma cancer cell lines which also showed same efficacy. The encouraging response of these drugs open new opportunities in cancer combination therapy.
In last few years, there has been large number of deals among pharmaceutical companies to evaluate novel combination of drugs for the management of cancer. In April,22 collaboration and supply agreement was signed between SpringWork Therapeutics and Regeneron to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with Regeneron’s investigational bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, REGN5458, in patients with relapsed or refractory multiple myeloma. F-Star Therapeutics announced clinical trial collaboration and supply agreement with Merck to evaluate FS120 in combination with Keytruda with the potential for early demonstration of clinical activity in specific tumor subtypes.
As per our report findings, the global cancer combination therapy is expected to surpass US$ 15 Billion by 2028. This is mainly attributed to large number of product approvals and their encouraging response in comparison to monotherapy. Further, it is analyzed that more than 10,000 clinical trials are ongoing in this segment which also suggests encouraging growth of the market in forecast period.